1. P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses. (21st January 2022) Authors: Rabinowitz, K M; Navon, M; Edelman-Klapper, H; Zittan, E; Bar-Gil Shitrit, A; Goren, I; Avni-Biron, I; Ollech, J E; Lichtenstein, L; Banai-Eran, H; Yanai, H; Snir, Y; Pauker, M H; Friedenberg, A; Levy-Barda, A; Segal, A; Broitman, Y; Maoz, E; Ovadia, B; Aharoni Golan, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P640 Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases. (30th January 2023) Authors: Edelman-Klapper, H; Rabinowitz, K M; Zittan, E; Bar-Gil Shitrit, A; Goren, I; Avni-Biron, I; Ollech, J E; Lichtenstein, L; Banai-Eran, H; Yanai, H; Snir, Y; Pauker, M H; Friedenberg, A; Levy-Barda, A; Segal, A; Broitman, Y; Maoz, E; Ovadia, B; Aharoni Golan, M; Shachar, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i772 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗